Register for our free email digests:
US Medical Inc.
Division of Globus Medical Inc./Facet Solutions Inc.
Latest From Cobalt Pharmaceuticals Inc.
With Pfizer’s blockbuster pain drug facing numerous generic challengers, the pharma gets FDA to agree not to accept any pregabalin ANDA that would include a “not less than” minimum level for R-isomer impurities; Pfizer’s patent certification arguments fall flat, however.
Pfizer gains another indication for its blockbuster pain drug Lyrica, even as it fights off generic competition from a variety of sources.
Pfizer Lyrica Citizen Petition Against Generics Argues Drug Impurities Should Have Ceiling, Not Floor
Lupin, Actavis and Wockhardt’s novel attempt to establish a “not less than” level for an impurity in their generic pregabalin as a tactic in patent litigation should be rejected, Pfizer argues.
Pfizer’s Lipitor goes generic—albeit with some decidedly unusual wrinkles. The biggest generic launch in history is a good moment to take stock of the transition away from the blockbuster model. The reaction to the milestone suggests that the industry’s critics may be having a harder time letting go of the old model than industry is.
- Medical Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Globus Medical Inc.
- Natus Medical Inc.
- US Medical Inc.
- Senior Management
- Contact Info
US Medical Inc.
Phone: (800) 607-7455
4701 Ironton St.
Denver, CO 80239
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.